Author

Christopher Brueckner

Observed names: Brueckner, Christopher T., Christopher T. Brueckner

Institution: Scholar Rock (United States)

Observed institutions: Bristol-Myers Squibb (United States), Scholar Rock (United States)

ORCID: 0000-0002-1740-7638

Observed ORCID: 0000-0002-1740-7638

OpenAlex ID: A5082962286

Selective inhibition of TGFβ1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape

2020 · Constance J. Martin, Abhishek Datta, et al. · Science Translational Medicine · 224

An antibody that inhibits TGF-β1 release from latent extracellular matrix complexes attenuates the progression of renal fibrosis

2024 · Justin W. Jackson, Frederick C. Streich Jr., et al. · Science Signaling · 26

Modulation of Biomarkers By BET Inhibitor, BMS-986158, Including JAK2 Variant Allele Frequency (VAF), Bone Marrow (BM) Fibrosis, and Reversal of Abnormal Cytokine Production in Intermediate- or High-Risk Myelofibrosis (MF)

2023 · Si Tuen Lee-Hoeflich, Christopher Brueckner, et al. · Blood

Abstract 3137: Characterizing heterogeneity of CD8 inflammation in biopsied tumor tissues using novel image analysis techniques

2021 · Charles William Caldwell, Will Paces, et al. · Cancer Research

Abstract 1801: Development of a comprehensive biomarker strategy to support phase 1 clinical trial of SRK-181 the latent TGFβ1 inhibitor

2021 · Christopher Brueckner, Ryan Faucette, et al. · Cancer Research

Abstract A12: Small molecule inhibitor of BCL2 in combination with RCHOP is effective in CD20 negative DLBCL.

2013 · Chaitali Dutta, Michele Mayo, et al. · Molecular Cancer Therapeutics

Works count: 7

Citation count: 251

H-index: 2

I10-index: 2